Neurological Disorders
Neurological disorders such as Alzheimer’s, Parkinson’s disease, multiple sclerosis, and spinal cord injuries disrupt the brain’s ability to communicate with the body. At JCRC-ABT CellGene Innovations, our regenerative therapies are designed to repair neural damage, slow disease progression, and improve overall neurological function, giving patients hope for a better quality of life.
What Are Neurological Disorders?
Neurological disorders encompass a wide range of conditions affecting the brain, spinal cord, and peripheral nerves. These conditions can result from genetics, injuries, infections, or aging. Common examples include Alzheimer’s, characterized by memory loss and cognitive decline, and Parkinson’s disease, which leads to tremors and mobility issues.
Symptoms vary widely depending on the condition but often include difficulty with coordination, muscle weakness, and cognitive impairments. Traditional treatments primarily manage symptoms, while regenerative therapies offer the potential to repair damaged neural tissues and restore lost function.
Benefits of Our Treatments for Neurological Disorders
Repairs Neural Damage
MSC-based stem cell therapies encourage the regeneration of damaged neurons, supporting improved cognitive and motor function.
Reduces Inflammation in the Nervous System
Chronic inflammation exacerbates neurological conditions. Immunotherapy helps regulate the immune response, protecting neural tissues from further damage.
Slows Disease Progression
Gene therapy addresses the genetic underpinnings of disorders like Alzheimer’s and Parkinson’s, slowing progression and preserving function.
Enhances Mobility and Independence
Regenerative treatments help restore strength and coordination, improving mobility and enabling patients to regain independence.
Why Choose Us?
At JCRC-ABT CellGene Innovations, we take a holistic approach to treating neurological disorders, combining advanced therapies with personalized care. Our goal is to repair neural connections, enhance quality of life, and offer patients renewed hope for the future.
1. What neurological disorders can JCRC-ABT treat?
We provide treatments for conditions like Alzheimer’s, Parkinson’s disease, multiple sclerosis, spinal cord injuries, and other neurological disorders.
2. Can these therapies reverse neurological damage?
While full reversal may not always be possible, our treatments aim to repair neural tissues, slow progression, and improve overall function.
3. Are regenerative therapies safe for neurological disorders?
Yes, our therapies are minimally invasive and adhere to strict safety protocols, ensuring effective and secure treatment options.
4. How soon can I expect results?
The timeline for improvements varies by condition, with some patients noticing benefits within weeks and others requiring several months.
5. Can these therapies be combined with traditional treatments?
Yes, our regenerative therapies can complement traditional treatments, enhancing overall outcomes and quality of life.
Achievements
Case Studies
Acute Lymphoblastic Leukemia (ALL)
A study in Blood highlighted the success of CAR-T cell therapy (tisagenlecleucel) in pediatric and young adult patients with relapsed/refractory ALL. Over 80% achieved complete remission within one month of treatment, with sustained responses observed in more than 50% at 12 months.
Non-Small Cell Lung Cancer (NSCLC)
Research published in Nature showed that combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) significantly improved progression-free survival in advanced NSCLC patients. The combination therapy demonstrated a 36% reduction in disease progression risk compared to chemotherapy.
Melanoma
A pivotal study in The New England Journal of Medicine demonstrated the efficacy of immune checkpoint inhibitors like pembrolizumab (anti-PD-1) in advanced melanoma. Patients experienced a 5-year overall survival rate of 43%, with durable tumor regression and manageable side effects, marking a breakthrough in melanoma treatment.
Cystic Fibrosis
A trial targeting CFTR gene mutations delivered via aerosolized vectors showed improved pulmonary function in patients with cystic fibrosis. Published in The Lancet Respiratory Medicine, the therapy reduced hospitalizations and improved quality of life metrics over 12 months.
Hemophilia B
Gene therapy using an AAV vector to deliver the FIX gene resulted in sustained Factor IX production in patients. A landmark study in Blood reported a significant reduction in bleeding episodes and factor replacement therapy use, lasting up to 5 years.
Leber’s Congenital Amaurosis (LCA)
The gene therapy Luxturna restored partial vision in patients with RPE65 gene mutations. Clinical trials demonstrated improved light sensitivity and navigation abilities, with effects persisting for over three years.
